A pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases

Zhang, Runjun; Liu, Renfeng; Liu, Chao; Pan, Lina; Qi, Yuantong; Cheng, Juan; Guo, Jian; Jia, Yong; Ding, Jun; Zhang, Jianxiang; Hu, Houyuan

doi:10.1016/j.biomaterials.2019.119605

Cited by 98 publications

(66 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Local acidification has been confirmed at inflamed sites of various diseases associated with acute and chronic inflammation, such as the peritoneum of peritonitis [ 87 ], injured arteries [ 88 ], ischemic sites [ 89 , 90 ], atherosclerotic plaques [ 91 ], asthmatic airways [ 92 ], rheumatic or gouty joints [ 93 ], and cerebrospinal fluid in the brain with meningitis [ 94 ]. Compared to healthy tissues, the inflamed areas generally display lower pH values.…”

Section: Inflammation and The Inflammatory Microenvironmentmentioning

confidence: 99%

Bioresponsive drug delivery systems for the treatment of inflammatory diseases

Ding

et al. 2020

Journal of Controlled Release

Self Cite

142

View full text Add to dashboard Cite

Inflammation is intimately related to the pathogenesis of numerous acute and chronic diseases like cardiovascular disease, inflammatory bowel disease, rheumatoid arthritis, and neurodegenerative diseases. Therefore anti-inflammatory therapy is a very promising strategy for the prevention and treatment of these inflammatory diseases. To overcome the shortcomings of existing anti-inflammatory agents and their traditional formulations, such as nonspecific tissue distribution and uncontrolled drug release, bioresponsive drug delivery systems have received much attention in recent years. In this review, we first provide a brief introduction of the pathogenesis of inflammation, with an emphasis on representative inflammatory cells and mediators in inflammatory microenvironments that serve as pathological fundamentals for rational design of bioresponsive carriers. Then we discuss different materials and delivery systems responsive to inflammation-associated biochemical signals, such as pH, reactive oxygen species, and specific enzymes. Also, applications of various bioresponsive drug delivery systems in the treatment of typical acute and chronic inflammatory diseases are described. Finally, crucial challenges in the future development and clinical translation of bioresponsive anti-inflammatory drug delivery systems are highlighted.

show abstract

Section: Inflammation and The Inflammatory Microenvironmentmentioning

confidence: 99%

Bioresponsive drug delivery systems for the treatment of inflammatory diseases

Ding

et al. 2020

Journal of Controlled Release

Self Cite

142

View full text Add to dashboard Cite

show abstract

“…On the other hand, ROS-scavenging nanoparticles can serve as an effective nanoplatform for site-specific delivery of therapeutics to the sites of vascular inflammation (Seshadri et al, 2010;Wu et al, 2018;Zhang R. et al, 2020). As welldocumented, substantially increased ROS levels are positively related to endothelial dysfunction and pathogenesis of restenosis after percutaneous coronary interventions (Juni et al, 2013).…”

Section: Cardiovascular Diseasesmentioning

confidence: 99%

“…injection more effectively attenuated neointimal hyperplasia than free RAP and a non-responsive nanotherapy. Further studies demonstrated that in vivo efficacy of the ROS-responsive RAP nanotherapy can be additionally improved by integrating with a pH-responsive β-CD material to afford a pH/ROS dual-responsive nanotherapy (Zhang R. et al, 2020). Of note, surface engineering of the dual-responsive nanoparticles via a peptide (KLWVLPKGGGC) targeting type IV collagen can notably increase their accumulation at injured carotid arteries, thereby potentiating in vivo efficacy of the dualresponsive RAP nanotherapy.…”

Section: Cardiovascular Diseasesmentioning

confidence: 99%

Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases

Chen

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Reactive oxygen species (ROS) are essential in regulating various physiological functions. However, overproduction of ROS is implicated in the pathogenesis of various inflammatory diseases. Antioxidant therapy has thus represented an effective strategy for the treatment of oxidative stress relevant inflammatory diseases. Conventional anti-oxidative agents showed limited in vivo effects owing to their non-specific distribution and low retention in disease sites. Over the past decades, significant achievements have been made in the development of antioxidant nanotherapies that exhibit multiple advantages such as excellent pharmacokinetics, stable anti-oxidative activity, and intrinsic ROS-scavenging properties. This review provides a comprehensive overview on recent advances in antioxidant nanotherapies, including ROS-scavenging inorganic nanoparticles, organic nanoparticles with intrinsic antioxidant activity, and drug-loaded anti-oxidant nanoparticles. We highlight the biomedical applications of antioxidant nanotherapies in the treatment of different inflammatory diseases, with an emphasis on inflammatory bowel disease, cardiovascular disease, and brain diseases. Current challenges and future perspectives to promote clinical translation of antioxidant nanotherapies are also briefly discussed.

show abstract

“…The characteristic conditions within the microenvironment of inflammatory tissues include lower pH value and higher ROS concentration [ 231 , 232 ]. Therefore, pH/ROS dual stimulus-responsive system is the most widely used treatment strategy for inflammation therapy [ 233 , 234 ]. For example, Almutairi et al designed a ROS-reactive dextran-drug conjugate (Nap-Dex) and blended Nap-Dex with an acid-sensitive acetal-dextran polymer (Ac-DEX) to obtain pH/ROS dual stimulus-responsive nanoparticles.…”

Section: Applications Of Stimulus-responsive Systemsmentioning

confidence: 99%

Stimulus-Responsive Nanomedicines for Disease Diagnosis and Treatment

Liu

Lovell

Zhang

et al. 2020

IJMS

View full text Add to dashboard Cite

Stimulus-responsive drug delivery systems generally aim to release the active pharmaceutical ingredient (API) in response to specific conditions and have recently been explored for disease treatments. These approaches can also be extended to molecular imaging to report on disease diagnosis and management. The stimuli used for activation are based on differences between the environment of the diseased or targeted sites, and normal tissues. Endogenous stimuli include pH, redox reactions, enzymatic activity, temperature and others. Exogenous site-specific stimuli include the use of magnetic fields, light, ultrasound and others. These endogenous or exogenous stimuli lead to structural changes or cleavage of the cargo carrier, leading to release of the API. A wide variety of stimulus-responsive systems have been developed—responsive to both a single stimulus or multiple stimuli—and represent a theranostic tool for disease treatment. In this review, stimuli commonly used in the development of theranostic nanoplatforms are enumerated. An emphasis on chemical structure and property relationships is provided, aiming to focus on insights for the design of stimulus-responsive delivery systems. Several examples of theranostic applications of these stimulus-responsive nanomedicines are discussed.

show abstract

A pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases

Cited by 98 publications

References 72 publications

Bioresponsive drug delivery systems for the treatment of inflammatory diseases

Bioresponsive drug delivery systems for the treatment of inflammatory diseases

Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases

Stimulus-Responsive Nanomedicines for Disease Diagnosis and Treatment

Contact Info

Product

Resources

About